Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 20/20 | 0.91 |
| ▸ | TBXA2R | P21731 | 19/20 | 0.91 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.65 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.65 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.65 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.65 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.65 |
| ▸ | PTGFR | P43088 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991162 | 0.95 | TBXA2R (1.00) | PTGDRTBXA2R | |
| SCHEMBL14175288 | 0.93 | TBXA2R (0.78) | PTGDRTBXA2RPTGER1PTGER3PTGER2 | |
| SCHEMBL22722578 | 0.88 | TBXA2R (0.90) | PTGDRTBXA2R | |
| SCHEMBL991127 | 0.85 | TBXA2R (1.00) | PTGDRTBXA2R | |
| SCHEMBL1253026 | 0.85 | PTGDR (1.00) | PTGDRTBXA2RPTGER1PTGER3PTGER2 | |
| SCHEMBL990560 | 0.83 | TBXA2R (0.84) | PTGDRTBXA2R | |
| SCHEMBL14449868 | 0.83 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL1042323 | 0.83 | PTGDR (1.00) | PTGDRTBXA2R | |
| SCHEMBL990454 | 0.82 | TBXA2R (1.00) | PTGDRTBXA2R | |
| SCHEMBL3872881 | 0.82 | PTGDR (1.00) | PTGDRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | CHENG KANG | 2010-03-25 | — | — | US | disclosed |
| US-20090233977-A1 | Method of Treating Atherosclerosis, dyslipidemias and related conditions | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20080139604-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139604-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | LDLR, HCAR1, FFAR1 | PTGDR 201/4885TBXA2R 37/4885PTGER1 300/4885 |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | LDLR, LPAR5, FFAR1 | PTGDR 164/4885TBXA2R 44/4885PTGER1 129/4885 |
| US-20090233977-A1 | Method of Treating Atherosclerosis, dyslipidemias and related conditions | LDLR, HCAR1, FFAR1 | PTGDR 201/4885TBXA2R 37/4885PTGER1 300/4885 |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | PTGDR 390/4885TBXA2R 56/4885PTGER1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.